New prospects for PET in prostate cancer imaging: a physicist's viewpoint

EJNMMI Physics

Volumn 1, Issue 1, 2014, Pages 1-11

  Conti, Maurizio ^a  

^a Siemens Healthcare Molecular Imaging   (United States)

Author keywords

Detectability; PET; Prostate cancer; Sensitivity; Spatial resolution; Time of flight

Indexed keywords

EID: 84957703774     PISSN: None     EISSN: 21977364     Source Type: Journal    
DOI: 10.1186/2197-7364-1-11     Document Type: Review

References (64)

1. Kotzerke J, Gschwend JE, Neumaier B: PET for prostate cancer imaging: still a quandary or the ultimate solution?J Nucl Med 2002, 43: 200–202.
2. Zaheer A, Cho SY, Pomper MG: New agents and techniques for imaging prostate cancer.J Nucl Med 2009, 50: 1387–1390. 10.2967/jnumed.109.061838
3. Farsad M, Schiavina R, Franceschelli A, Sanguedolce F, Castellucci P, Bertaccini A, Brunocilla E, Manferrari F, Concetti S, Garofalo M, Rocca C, Borghesi M, Franchi R, Fanti S, Nanni C, Martorana G: Positron-emission tomography in imaging and staging prostate cancer.Cancer Biomark 2008, 4: 277–284.
4. Apolo AB, Pandit-Taskar N, Morris MJ: Novel tracers and their development for the imaging of metastatic prostate cancer.J Nucl Med 2008, 49: 2031–2041. 10.2967/jnumed.108.050658
5. Fox JJ, Schoder H, Larson SM: Molecular imaging of prostate cancer.Curr Opin Urol 2012, 22: 320–327. 10.1097/MOU.0b013e32835483d5
6. Jadvar H: Molecular imaging of prostate cancer: PET radiotracers.AJR Am J Roentgenol 2012, 199: 278–291. 10.2214/AJR.12.8816
7. Lutje S, Boerman OC, Van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, Mulders PF: Prospects in radionuclide imaging of prostate cancer.Prostate 2012, 72: 1262–1272. 10.1002/pros.22462
8. 18F-fluorocholine PET.J Nucl Med 2006, 47: 262–269.
9. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J: Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.J Urol 2000, 164: 400–404. 10.1016/S0022-5347(05)67370-3
10. Picchio M, Giovannini E, Crivellaro C, Gianolli L, Di Muzio N, Messa C: Clinical evidence on PET/CT for radiation therapy planning in prostate cancer.Radiother Oncol 2010, 96: 347–350. 10.1016/j.radonc.2010.07.016
11. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P: PET/CT imaging and radioimmunotherapy of prostate cancer.Semin Nucl Med 2011, 41: 29–44. 10.1053/j.semnuclmed.2010.08.005
12. 11C-choline.J Nucl Med 2011, 52: 81–89. 10.2967/jnumed.110.077941
13. Schoeder H, Larson SM: Positron emission tomography for prostate cancer.Semin Nucl Med 2004,34(4):274–292. 10.1053/j.semnuclmed.2004.06.004
14. 11C-choline PET.J Nucl Med 2003, 44: 331–335.
15. 11C-acetate.J Nucl Med 2003, 44: 556–558.
16. 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings.J Nucl Med 2006, 47: 938–944.
17. 11C-choline PET/CT.J Nucl Med 2006, 47: 1249–1254.
18. 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.J Nucl Med 2002, 43: 187–199.
19. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.Cancer Res 2000, 61: 110–117.
20. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.J Nucl Med 2003, 44: 549–555.
21. 11C-acetate kinetics of prostate cancer.J Nucl Med 2008, 49: 206–215. 10.2967/jnumed.107.044453
22. 18F-fluoride PET/CT.J Nucl Med 2006, 47: 287–297.
23. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM: Initial experience with the radiotracer anti-1-amino-3–18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.J Nucl Med 2007, 48: 56–63.
24. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.J Nucl Med 2010, 51: 1293–1300. 10.2967/jnumed.110.076174
25. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL: Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.Cancer Discov 2012, 2: 320–327. 10.1158/2159-8290.CD-11-0316
26. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.Eur J Nucl Med Mol Imaging 2013, 40: 486–495. 10.1007/s00259-012-2298-2
27. 18F]DCFBC: a new imaging probe for prostate cancer.Clin Cancer Res 2008, 14: 3036–3043. 10.1158/1078-0432.CCR-07-1517
28. Wu AM: Antibodies and antimatter: the resurgence of immuno-PET.J Nucl Med 2009, 50: 2–5.
29. Wu AM: Engineered antibodies for molecular imaging of cancer.Methods 2014, 65: 139–147. 10.1016/j.ymeth.2013.09.015
30. 11C-acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.J Nucl Med 2012, 53: 538–545. 10.2967/jnumed.111.096032
31. Panin VY, Kehren F, Michel C, Casey M: Fully 3-D PET reconstruction with system matrix derived from point source measurements.IEEE Trans Med Imaging 2006, 25: 907–921.
32. Conti M: State of the art and challenges of time-of-flight PET.Phys Med 2009, 25: 1–11. 10.1016/j.ejmp.2008.10.001
33. Conti M: Focus on time-of-flight PET: the benefits of improved time resolution.Eur J Nucl Med Mol Imaging 2011, 38: 1147–1157. 10.1007/s00259-010-1711-y
34. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW: Impact of time-of-flight on PET tumor detection.J Nucl Med 2009, 50: 1315–1323. 10.2967/jnumed.109.063016
35. Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G: Benefit of time-of-flight in PET: experimental and clinical results.J Nucl Med 2008, 49: 462–470. 10.2967/jnumed.107.044834
36. Lois C, Jakoby BW, Long MJ, Hubner KF, Barker DW, Casey ME, Conti M, Panin VY, Kadrmas DJ, Townsend DW: An assessment of the impact of incorporating time-of-flight information into clinical PET/CT imaging.J Nucl Med 2010, 51: 237–245. 10.2967/jnumed.109.068098
37. Schaefferkoetter J, Casey M, Townsend D, El Fakhri G: Clinical impact of time-of-flight and point response modeling in PET reconstructions: a lesion detection study.Phys Med Biol 2013, 58: 1465–1478. 10.1088/0031-9155/58/5/1465
38. Jakoby B, Bercier Y, Conti M, Casey M, Bendriem B, Townsend D: Physical and clinical performance of the mCT time-of-flight PET/CT scanner.Phys Med Biol 2011, 56: 2375–2389. 10.1088/0031-9155/56/8/004
39. Morey AM, Noo F, Kadrmas DJ: Improved PET lesion-detection performance using 2mm pixels. In IEEE Nuclear Science Symposium and Medical Imaging Conference. Edited by: Choi Y. Piscataway: IEEE; 2013:1–4.
40. Clinthorne N, Brzezinski K, Chesi E, Cochran E, Grkovski M, Grošičar B, Honscheid K, Huh S, Kagan H, Lacasta C, Linhart V, Mikuž M, Smith S, Stankova V, Studen A, Weilhammer P, žontar D: Silicon as an unconventional detector in positron emission tomography.Nucl Instrum Methods Phys Res A 2013, 699: 216–220.
41. Garibaldi F, De Leo R, Ranieri A, Loddo F, Floresta M, Tamma C, Gabrielli A, Giorgi F, Cusanno F, Musico P, Perrino R, Finocchiaro P, Cosentino L, Pappalardo A, Meddi F, Maraviglia B, Giove F, Gili T, Capuani S, Turisini M, Clinthorne N, Huh S, Majewski S, Lucentini M, Gricia M, Giuliani F, Monno E: TOPEM: a multimodality probe (PET TOF, MRI, and MRS) for diagnosis and follow up of prostate cancer. In IEEE Nuclear Science Symposium Conference Record Edited by: Ziock K. 2010, 2442–2444.
42. Janecek M, Wu H, Tai Y-C: High resolution insert for clinical whole body PET scanners: design and optimization. In IEEE Nuclear Science Symposium Conference Record. Edited by: Seibert JA. Piscataway: IEEE; 2004:3849–3852.
43. Stolin AV, Majewski S, Jaliparthi G, Raylman RR: Construction and evaluation of a prototype high resolution, silicon photomultiplier-based, tandem positron emission tomography system.IEEE Trans Nucl Sci 2013, 60: 82–86.
44. Tai YC, Wu H, Pal D, O'Sullivan JA: Virtual-pinhole PET.J Nucl Med 2008, 49: 471–479. 10.2967/jnumed.107.043034
45. Zhou J, Qi J: Theoretical analysis and simulation study of a high-resolution zoom-in PET system.Phys Med Biol 2009, 54: 5193–5208. 10.1088/0031-9155/54/17/008
46. Huber JS, Moses WW, Pouliot J, Hsu I: Dual-modality PET/ultrasound imaging of the prostate. In IEEE Nuclear Science Symposium Conference Record. Edited by: Seibert JA. Piscataway: IEEE; 2004:2187–2190.
47. Majewski S, Stolin A, Delfino E, Martone P, Proffitt J: High resolution fast stereotactic PET imager for prostate biopsy. In IEEE Nuclear Science Symposium and Medical Imaging Conference. Edited by: Chmeissani M. Piscataway: IEEE; 2011:3406–3409.
48. Turkington TG, Hawk T, Coleman R, Smith M, Majewski S, Kross B, Wojcik R, Weisenberger AG, DeGrado TR, Coleman RE: PET prostate imaging with small planar detectors. In IEEE Nuclear Science Symposium Conference Record. Edited by: Seibert JA. Piscataway: IEEE; 2004:2806–2809.
49. Bal H, Guerin L, Casey ME, Conti M, Eriksson L, Michel C, Fanti S, Pettinato C, Adler S, Choyke P: Improving PET spatial resolution and detectability for prostate cancer imaging.Phys Med Biol 2014,59(15):4411–4426. 10.1088/0031-9155/59/15/4411
50. 18F choline PET/CT using time-of-flight reconstruction algorithm in prostate cancer patients with biochemical recurrence.Clin Nucl Med 2014, 39: e197-e201. 10.1097/RLU.0b013e3182a23d37
51. 11C] choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.Eur J Nucl Med Mol Imaging 2014, 41: 694–701. 10.1007/s00259-013-2634-1
52. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.J Nucl Med 2013, 54: 699–706. 10.2967/jnumed.112.111153
53. 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancer.Clin Nucl Med 2012, 37: 918–919. 10.1097/RLU.0b013e31825b23a6
54. 11C]choline PET/MR with PET/CT in patients with prostate cancer.Eur J Nucl Med Mol Imaging 2013, 40: 1486–1499. 10.1007/s00259-013-2467-y
55. 18F]choline PET/CT.Eur J Nucl Med Mol Imaging 2014, 41: 79–88. 10.1007/s00259-013-2560-2
56. 13C lactate.J Magn Reson 2012, 217: 41–47.
57. Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, Choyke PL, Harisinghani M: Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.AJR Am J Roentgenol 2012, 198: 1277–1288. 10.2214/AJR.12.8510
58. Turkbey B, Choyke PL: Multiparametric MRI and prostate cancer diagnosis and risk stratification.Curr Opin Urol 2012, 22: 310–315. 10.1097/MOU.0b013e32835481c2
59. Bouchelouche K, Turkbey B, Choyke P, Capala J: Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging.Curr Urol Rep 2010, 11: 180–190. 10.1007/s11934-010-0105-9
60. Hartenbach M, Hartenbach S, Bechtloff W, Danz B, Kraft K, Klemenz B, Sparwasser C, Hacker M: Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial.Clin Can Res 2014,20(12):3244–3253. 10.1158/1078-0432.CCR-13-2653
61. 11C]choline uptake in prostate cancer: a PET study.Eur Jour Nucl Med Mol Imag 2004, 31: 317–324. 10.1007/s00259-003-1377-9
62. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, Chenevert T, Piert M: Introducing parametric fusion PET/MRI of primary prostate cancer.Jour Nucl Med 2012, 53: 546–551. 10.2967/jnumed.111.091421
63. 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization.Cancer Biomarkers 2008, 4: 263–276.
64. 11C-choline PET/CT using multimodality fusion techniques.J Nucl Med 2009, 50: 1585–1593. 10.2967/jnumed.109.063396